Improving Outcomes in Patients
With Bipolar Depression:
A Comprehensive Review


Online InfoPack Materials

Multimedia InfoPack

An online version of the InfoPack, including “test your knowledge” questions.

InfoPack PDF

A printer-friendly online version of the InfoPack just as it appeared in print.


Faculty Presenters

  • Andrew A. Nierenberg, MD (Chair)
  • Medical Director, Bipolar Research Program, Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston, Massachusetts
  • Roger S. McIntyre, MD, FRCPC
  • Professor of Psychiatry and Pharmacology, University of Toronto and Head, Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada


  • Gary S. Sachs, MD
  • Director, Bipolar Clinic, Massachusetts General Hospital, Partners Bipolar Treatment Center, Boston, Massachusetts



Faculty Disclosure

Dr Nierenberg has been a consultant for Abbott, American Psychiatric Association, Appliance Computing (Mindsite), Basliea, Brain Cells, Brandeis University, Bristol-Myers Squibb, Clintara, Corcept, Dainippon Sumitomo (now Sunovion), Dey, Eli Lilly, EpiQ LP/Mylan, Forest, Genaissance, Genentech, GlaxoSmithKline, Hoffman LaRoche, InfoMedic, Janssen, Jazz, Lundbeck, Medavante,Merck, Methylation Sciences, Naurex, Novartis, PamLabs, Pfizer, PGx Health, Ridge Diagnostics, Schering-Plough, Shire, Somerset, Sunovion, Takeda/Lundbeck, Targacept, and Teva; consulted through the MGH Clinical Trials Network and Institute (CTNI) for AstraZeneca, Brain Cells, Dainippon Sumitomo/Sepracor, Johnson & Johnson, Labopharm, Merck, Methylation Science, Novartis, PGx Health, Schering-Plough, Shire, Takeda/Lundbeck, and Targacept; has received grant/research support from AHRQ, American Foundation for Suicide Prevention, Brain and Behavior Research Foundation, Bristol-Myers Squibb, Cederroth, Cephalon, Cyberonics, Elan, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Lichtwer, Marriott Foundation, Mylan, NIMH, PamLabs, PCORI, Pfizer, Shire, Stanley Foundation, Takeda, and Wyeth-Ayerst; has received honoraria from American Drug Utilization Review, American Society for Clinical Psychopharmacology, APSARD, Baystate Medical Center, Belvoir Publishing, Brandeis University, Bristol-Myers Squibb, Columbia University, CRICO, Dartmouth Medical School, Health New England, Harold Grinspoon Charitable Foundation, Hillside Hospital, Imedex, International Society for Bipolar Disorder, ISBD, Israel Society for Biological Psychiatry, Johns Hopkins University, MBL Publishing, Medscape, MGH Psychiatry Academy, MJ Consulting, National Association of Continuing Education, New York State, Physicians Postgraduate Press, SciMed, Slack Publishing, SUNY Buffalo, University of Miami, University of Michigan, University of Texas Southwestern Dallas, University of Pisa, University of Wisconsin, University of Wisconsin at Madison, and Wolters Klower Publishing; has stock ownership in Appliance Computing (MindSite), Brain Cells, and Medavante; and holds copyright to Clinical Positive Affect Scale and the MGH Structured Clinical Interview for the Montgomery-Asberg Depression Scale exclusively licensed to the MGH Clinical Trials Network and Institute (CTNI). Dr Nierenberg has not been on any speakers bureaus since 2003.

Dr McIntyre has been on advisory boards for Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, France Foundation, GlaxoSmithKline, Janssen-Ortho, Lundbeck, Merck, Organon, Pfizer, and Shire; been on the speakers bureaus for Astra-Zeneca, Eli Lilly, Janssen- Ortho, Lundbeck, Merck, and Pfizer; and received research grants from Astra-Zeneca, Eli Lilly, Janssen-Ortho, Lundbeck, NARSAD, NIMH, Pfizer, Shire, and Stanley Medical Research Institute.

Dr Sachs has been consultant for AstraZeneca, Janssen, Lundbeck, Sunovion, and Takeda; has received grant/research support from NIMH; is on the speakers/advisory boards for Merck, Takeda, Sunovion and Otsuka; is a stock shareholder of Oracle, AthenaHealth, McKesson, Collaborative Care Initiative; and is an employee of Bracket and Massachusetts General Hospital.


This InfoPack is based on a series of teleconferences by 3 experts on the treatment of Bipolar I disorder. These teleconferences were held in July and August 2014. This evidence-based, peer-reviewed InfoPack was prepared by Healthcare Global Village, Inc. Financial support for the preparation and dissemination of this InfoPack was provided by Sunovion Pharmaceuticals, Inc. The authors acknowledge Nancy Groves, MS, Healthcare Global Village, Inc, for editorial assistance in development of the manuscripts. The opinions expressed herein are those of the authors and do not necessarily reflect the views of Healthcare Global Village, Inc; the publisher; the American Society of Clinical Psychopharmacology; or the commercial supporter.

Review Process

The faculty for this InfoPack discussed the content in a series of peer-review planning teleconferences, the chair and faculty reviewed the InfoPack for accuracy, and a member of the Journal Editorial Board who is without conflict of interest reviewed the InfoPack to determine whether the material is evidence-based and objective.

​​​​​​​​​​ The Journal of Clinical Psychiatry The Primary Care Companion for CNS Disorders The CME Institute Neurology Knowledge Terms of Use Privacy Policy